Auguste Gaddah

发表

Flexible Modeling in the Koziol-Green Model by a Copula Function

R. Braekers, Auguste Gaddah, 2011 .

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

V. Bockstal, Benoît Callendret, Auguste Gaddah, 2020, The Journal of infectious diseases.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.

Y. Lévy, A. Pollard, J. Lelièvre, 2020, The Lancet. Infectious diseases.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

H. Schuitemaker, D. Heerwegh, R. Roozendaal, 2022, npj Vaccines.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

M. McElrath, O. Anzala, D. Heerwegh, 2022, PLoS medicine.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, npj Vaccines.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

M. McElrath, O. Anzala, D. Heerwegh, 2021, PLoS medicine.

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children

D. Watson-Jones, Pauline Akoo, D. Ishola, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

D. Watson-Jones, C. McLean, G. Deen, 2022, The Lancet. Infectious diseases.

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV

L. Jagodzinski, A. Esber, I. Jani, 2021, Open Forum Infectious Diseases.

Hasselt University Center for Statistics

Auguste Gaddah, Auguste Gaddah, 2009 .

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, NPJ vaccines.

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

D. Watson-Jones, O. Anzala, S. Sirima, 2023, EBioMedicine.

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2023, Frontiers in immunology.

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

D. Watson-Jones, C. Drakeley, S. Soremekun, 2023, Vaccines.

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial

L. Jagodzinski, M. Robb, M. Eller, 2024, Vaccines.

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Auguste Gaddah, M. Douoguih, Babajide Keshinro, 2024, Human vaccines & immunotherapeutics.

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

S. Sirima, J. Lelièvre, H. Kibuuka, 2024, Vaccines.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.

D. Watson-Jones, E. D’Ortenzio, D. Ishola, 2023, The Lancet. Global health.

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.

D. Watson-Jones, P. Kaleebu, O. Anzala, 2023, Vaccine.